Long-term survival with complete remission after hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer: a case report.
We report a case of long-term survival with complete remission after hepatic arterial infusion chemotherapy (HAIC) for liver metastasis from gastric cancer. A 62-year-old man underwent radical distal gastrectomy with D2 lymphadenectomy for an advanced gastric cancer. Solitary liver metastasis in the S2/3 segment was detected 26 months after initial surgery. The patient underwent HAIC with systemic chemotherapy. Serum CEA levels rapidly decreased, and CT scan showed disappearance of the tumor with complete clinical response 8 months after HAIC. HAIC was performed 83 times in total, until the hepatic artery proper was adequately obstructed. No severe adverse effects were observed during HAIC treatment. The patient is still disease-free without further chemotherapy more than 12 years after HAIC. Our experience suggests that HAIC should be considered as a treatment option in patients with resectable liver metastasis from gastric cancer. However, further studies are needed to verify the validity of HAIC for resectable liver metastasis from gastric cancer.
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. t-toyokawa@med.osaka-cu.ac.jp.
Takahiro
T
Toyokawa
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. masaichi@med.osaka-cu.ac.jp.
Masaichi
M
Ohira
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. m1157473@med.osaka-cu.ac.jp.
Katsunobu
K
Sakurai
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. ramano@med.osaka-cu.ac.jp.
Ryosuke
R
Amano
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. m2047971@med.osaka-cu.ac.jp.
Naoshi
N
Kubo
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. hiroakitan@med.osaka-cu.ac.jp.
Hiroaki
H
Tanaka
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. m8231627@med.osaka-cu.ac.jp.
Kazuya
K
Muguruma
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. hirakawa@med.osaka-cu.ac.jp.
Kosei
K
Hirakawa
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D015996:Survival Rate